SCHEMBL13617885

SCHEMBL13617885

CCOC(CCOC(=O)Oc1ccc([N+](=O)[O-])cc1)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.53
MAPT P10636 4/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
BCL9 O00512 1/20 0.50
CTNNB1 P35222 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GAA P10253 1/20 0.46
MGLL Q99685 2/20 0.45
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ACHE P22303 2/20 0.42
SLC6A4 P31645 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31011370 0.87 HTR2A (0.55) HTR2AMAPTCRHBPCRHR2BCL9
SCHEMBL6600772 0.84 HTR2A (0.61) HTR2AMAPTCRHBPCRHR2BCL9
SCHEMBL7424537 0.83 HTR2A (0.55) HTR2ABCL9CTNNB1ALDH1A1NPC1
SCHEMBL2597400 0.82 BCL9 (0.63) HTR2AMAPTCRHBPCRHR2BCL9
SCHEMBL278663 0.82 BCL9 (0.62) HTR2AMAPTCRHBPCRHR2BCL9
SCHEMBL409598 0.82 HTR2A (0.59) HTR2AMAPTCRHBPCRHR2BCL9
SCHEMBL9396560 0.82 ATM (0.59) MAPTCRHBPCRHR2L3MBTL1ALDH1A1
SCHEMBL19201774 0.82 HTR2A (0.58) HTR2AMAPTCRHBPCRHR2BCL9
SCHEMBL18699060 0.81 BCL9 (0.55) HTR2AMAPTCRHBPCRHR2BCL9
SCHEMBL1144551 0.81 MGLL (0.62) HTR2AMAPTCRHBPCRHR2BCL9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 HTR2A 3778/4885MAPT 1868/4885CRHBP 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.